Navigation Links
Aderans Research Acquires Intercytex Assets
Date:3/25/2010

(Atlanta, GA, March 24, 2010) Aderans Research Institute Inc. (ARI) announced it purchased key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a leading UK hair regeneration company.

Atlanta, GA (PRWeb UK) March 25, 2010 -- Aderans Research Institute Inc. (ARI) announced it purchased key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a leading UK hair regeneration company. The acquisition represents a significant consolidation within the hair regeneration industry, as ARI is absorbing the scientific assets of a company that was its leading competitor.

“This acquisition is a major step forward for ARI,” said Vern Liebmann, Vice President, Operations. “Through this deal, we’ve been able to consolidate the majority of key patents and know-how in the hair regeneration field, an achievement that can accelerate our ability to deliver a commercially viable product to market. This acquisition was only possible thanks to the considerable financial support of Aderans Holdings Company, Ltd., of Japan.”

The purchase includes assets related to the ICX-TRC product that Regenerative Medicine Assets Limited had been developing. ICX-TRC is an autologous hair regeneration therapy for the treatment of male pattern baldness and female diffuse alopecia.

The deal comes as ARI is expanding its Phase 2 clinical study of cell-based hair regeneration, in which it recently treated the trial’s 100th subject. “We’ve acquired important proprietary knowledge that includes Intercytex’s clinical efforts to date,” noted Ken Washenik, MD PhD, Executive Vice President. “This information should substantially augment our ongoing efforts to produce a cell-based treatment for hair loss.”

“Cellular regeneration represents the leading edge of research into hair loss,” said Kurt Stenn, MD, Vice President and Chief Scientific Officer. “Combining the knowledge stores of two of the leading companies in this field is a major step forward in our efforts to pioneer a process of cellular hair regeneration that can deliver enhanced hair growth to millions of people around the world.”

About Aderans Research

Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Holdings Company, Ltd., the world’s largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration.

More information on ARI’s study outcomes will be released as studies unfold. To see ARI’s latest clinical updates, please visit http://aderansresearch.com/ari_clinicalupdates.html

Additional information on ARI can be found at www.aderansresearch.com.

Learn more about Aderans Holdings Company, Ltd. at http://www.aderans.co.jp/e/company/

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3774184.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Aderans Research Treats One-Hundredth Subject in Clinical Study
2. Researchers Identify 2 Genes Linked to Fatty Liver Disease
3. NIA researchers find gene to explain mouse embryonic stem cell immortality
4. Researchers discover fundamental step in immune-system development
5. Sino Veda Herbal Product Maker Goes Natural in Edmonton Research Park
6. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
7. BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now
8. Childrens Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami
9. Innovative Service Revolutionizes How Businesses Research Product Sales Potential
10. MAYO Communications Retained by MAMMOJAM 2010 Dr. Susan Love Research Foundation Event
11. Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aderans Research Acquires Intercytex Assets 
(Date:5/27/2017)... ... , ... A May 8 article on CBCNews reports that nearly ... that are not responsive to antibiotics nevertheless obtain prescriptions for them. The article goes ... the problem both in Canada and the United States. Dr. Michael Farzam of House ...
(Date:5/26/2017)... ... 2017 , ... Mediaplanet is proud to announce the launch of its newest ... educate readers on how to take care of all aspects of their skin. , ... melanoma. Dancing with the Stars professional, Witney Carson, shares her journey with the disease ...
(Date:5/26/2017)... Santa Clara, Calif. (PRWEB) , ... May 26, ... ... technology, announces the integration of the CareFusion NOX-T3 portable sleep monitor with its ... that provides a consistent, browser-based interface for diagnostic device operations. With this platform, ...
(Date:5/26/2017)... Germantown, MD (PRWEB) , ... May 26, 2017 , ... ... the anti-stress Antzy Top gadget will continue to be available at a discounted crowdfunding ... people deal with stress wherever they are, I also wanted to bring a fidget ...
(Date:5/26/2017)... ... 26, 2017 , ... “When the Stars Lead Home”: a poignant story of ... author Laura Weigel Douglas, an avid reader who lives in the Pacific Northwest with ... like Green Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy ...
Breaking Medicine News(10 mins):
(Date:5/11/2017)... 2017  Thornhill Research Inc. ( Toronto, ... $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the ... Corporation (CCC) ( Ottawa, Ontario, Canada ... general anesthesia to patients requiring emergency medical procedures ... Marine Corps have been a longtime partner with ...
(Date:5/10/2017)... BARRINGTON, Ill. , May 10, 2017 ... medicine today; unfortunately its costs have also spiraled to ... are being sent to radiology than ever before as ... and diagnosis.  For a patient with lower back pain ... prove no anatomical reason for pain, resulting in entirely ...
(Date:5/9/2017)...  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... focused on the development of oral drug delivery ... Office has granted Oramed a patent titled, "Methods ... patent covers Oramed,s invention of an oral glucagon-like ... incretin hormone that stimulates the secretion of insulin ...
Breaking Medicine Technology: